Infinity Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported loss from operations of $27,661,000 against $10,161,000 a year ago. Net loss was $27,326,000 or $0.57 per basic and diluted share against $10,722,000 or $0.40 per basic and diluted share a year ago. The company did not record any revenue during the quarter. Total revenue was $25.2 million for the same period in 2012, which was composed of $24.2 million for reimbursed R&D services performed under previous strategic alliance with Purdue/Mundipharma and $1 million from amortization of deferred revenue associated with the grants of rights and licenses under this alliance.

Infinity Pharmaceuticals, Inc., Q1 2013 Earnings Call, May 07, 2013

Infinity Pharmaceuticals, Inc. announced that on April 3, 2013, Christopher M. Lindblom, the company's Vice President, Accounting and Finance, who also served as company's principal accounting officer, informed the company that he will be resigning from his position effective May 3, 2013. On April 7, 2013, the company's board of directors appointed Lawrence E. Bloch, M.D., J.D. as the company's principal accounting officer effective immediately. Dr. Bloch, age 47, has served as the company's Executive Vice President, Chief Financial Officer and Chief Business Officer since July 2012. Prior to joining the company, Dr. Bloch served as chief executive officer of NeurAxon, Inc.